Increased Demand Causes Fuji to Expand Astaxanthin Production

April 22, 2011

The plan is to double current production capacity.

Fuji Chemical Industry Company, Ltd., (Toyama, Japan) announced plans to double production of its AstaReal natural astaxanthin (Haematococcus pluavialis) in response to increased demand worldwide, the company says. Production will ramp up at Fuji’s wholly owned subsidiary BioReal AB in Gustavsberg, Sweden.

The company says demand has been driven by increasing science supporting AstaReal’s “positive effects on health,” along with AstaReal’s GRAS approval in the United States last year.

The company says that production at the BioReal facility can be expanded rapidly. The plan is to double current production capacity.